je.st
news
Home
› Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol
Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol
2015-03-22 06:59:40| Biotech - Topix.net
Amgen today announced that an application seeking marketing approval of RepathaTM for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan. Repatha is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
Tags: of
high
japan
marketing
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||